Next Phase Newsletter

The firm is a venture capital firm founded in 2020 and is located in Texas. The firm is different from a traditional VC in that it focuses on investing, building and scaling life science start ups. The goal is to co-innovate and grow with the startups they invest in. The firm has a fund that is financed by 35 angel groups as well as a hedge fund. Investments are mainly in the form of equity and in-licensing, but the firm is flexible on a case-by-case basis with convertible notes. The firm has 7 life science companies in their portfolio to date. The firm’s main focus is biotech, medtech, and AI and machine learning technologies. The firm’s goal is to build innovations in hospitals that transform the lives of patients and make doctors jobs easier. The firm focuses on Pre-Seed, Seed and Series A financing rounds. The firm is open to global opportunities.

The firm focus on AI, machine learning, and other biotech/medtech technologies, and within those domains, are open to all 4 main sectors. The firm looks for technologies in: consumer health, connected health practices, patient engagement related arenas, telehealth, distal therapeutics, and consumer health solutions and services. The firm doesn’t focus on traditional medical devices, but is looking to invest in “smart” medical devices that support connected health practices. The firm is open to most indications, especially oncology, women’s health, mental health, respiratory, cardiology, and pediatrics. The firm is not interested in drugs therapeutics or immunology with the exception of mRNA vaccines. The firm invests in pre-clinical companies.

The firm is looking for a team that they can work and co-innovate with and do channel partnering with to scale their businesses. For this firm, the concept or idea is the most important part and they are looking for more than what companies built today, they look for the future impact. Interested companies should have management teams that are in alignment with the firm’s values and that their end outcome is patient success. The firm can lead or co-invest on a case by case basis and will seek board seat representation on a case by case basis as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The corporate venture arm of a large company was founded in 2016 and since then has made 30 investments. One of the firm’s main focus areas is in the longevity space as well as long term care. Within this space, the firm is open to all four sectors. The firm currently has a $350M fund and focuses mainly on Series A and B rounds in the form of equity, but will occasionally look at Seed rounds or late-stage rounds as well on a case by case basis. The firm is open to global opportunities, with a focus in US and Israeli markets.

The firm focuses on longevity investments and are open to all four life science sectors within that space. The firm looks for companies that have healthcare platforms that relate to monitoring and managing chronic conditions, as well as long term care and care coordination platforms. The firm is also interested in fintech companies focused on the retirement space as well as health data companies where the firm can find sources of data for life insurance and underwriting services. The firm will invest in all 3 classes of medical devices. The firm is not interested in biomedical companies and they do not invest in pre-clinical or pre-prototype companies.

The firm is open to all types of management teams from any type of background. The firm does not lead investments and prefers to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe is entirely specialized in and focused on investing in early-stage oncology drug development companies. For its most recent fund, the firm seeks to invest in an estimated 10 biotechnology start-ups in cancer treatment. Typical investments are made in equity and with an average ticket size of 10 million Euros over a period of 5 to 7 years. In addition, the firm seeks to invest 1-2 million Euros in promising academic cancer research projects over a period of 18 months with the aim to transition these projects to NewCo’s. The firm seeks a lead investor role in companies based in the Netherlands and Belgium, and a co-investor role in other regions. The firm prefers syndicated investments with like-minded investors with equal ticket sizes. The firm’s main focus is on European companies, although they will consider US opportunities.

The firm focuses on a wide spectrum of cancer treatment, including but not limited to small molecules, antibodies, gene therapy, cell therapy, and immunotherapy. The firm supports early-stage companies from incubator stage and preclinical through phase 1. The firm prefers to invest in companies that have underlying platform technologies.

The firm can support management teams by being operationally involved on an interim basis in companies based in the country of their headquarters, and will frequently set-up companies from scratch with the inventors. The firm can help refine the business plan, R&D plans and provide financial, IP, IT, legal, HR support. If needed, the firm will take up interim-management roles.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based single family office is very flexible in terms of investment size they are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. The firm’s preferred geography is North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell-based therapeutics and other immune-directed  therapies. The firm generally will not consider single target small molecules, biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease-modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets.

 The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency. For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage healthcare focused venture capital firm headquartered in the East Coast USA invests in Pre-Seed, Seed and Series A rounds across all four life science sectors. The firm has a current fund of $50M that they are actively raising and investing out of. The typical check size ranges from $100K – $1.5M in the form of priced rounds, equity, SAFEs or convertible notes. The firm invests globally, with a focus on helping companies outside of the US get into the US market.

The firm seeks to make investments in all four life science sectors, and is agnostic to subsector and indication. The firm is looking to provide start-ups with capital as well as advisory and strategic input when needed. The firm is open to pre-clinical companies and is open to all three classes of medical devices.

The firm is open to all types of management teams including first time entrepreneurs and underrepresented groups. The firm likes to typically lead investments, and will seek a board seat, but is also open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital company was founded in 2007 and based in Durham, North Carolina with additional office in Orlando, Florida. The firm has approximately $38 million in total assets under management. The firm seeks to make equity investments in 2 to 3 companies in the next 6 to 9 months. The average first investment in a company is $0.1 million to $ 0.75 million, though it can invest up to $ 1.5 million, depending on the opportunity. The firm prefers to invest in seed and early- stage companies located in the Southeast and Mid-Atlantic regions of the US with a focus in the states of North Carolina and Florida.

The firm is currently looking for new investment opportunities in Medical Technology and Healthcare IT spaces. The firm is most interested in companies producing medical devices and software. The firm is very opportunistic in terms of medical devices, and it would consider companies operating within any subsector of medical technology. The firm generally makes investments in pre-clinical and prototype stages within medical technology sector.

The firm will consider pre-revenue companies and make initial investments in companies with no revenues. The firm prefers to invest in technologies that are disruptive to existing markets or enable entirely new ones. The firm will not consider any biotechnology and pharmaceutical companies, and additionally would not be interested in growth companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Based in San Francisco, CA, and has an additional office in Japan, a venture capital firm is investing from a new fund that closed in 2016. The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions. It has invested thus far in some well-known companies.

The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.